1Division
of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases,
Centers for Disease Control and Prevention, Atlanta, GA, USA; 2Division of HIV/AIDS Prevention
– Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta,
GA, USA; 3Division of Infectious Disease, School of Medicine, Wayne State University, Detroit, MI, USA; 4Infectious
Disease Division, Department of Medicine, Brown University, Providence, RI, USA; 5Departments
of Medicine and Epidemiology and Social Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA;
6Department of Epidemiology, School of
Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA
The CCR5-Δ32 genotype
is known to influence HIV-1 transmission and disease. We genotyped 1301 US women
of various races/ethnicities participating in the HIV Epidemiologic Research Study.
None was homozygous for CCR5-Δ32. The distribution of heterozygotes was similar in HIV-1 infected and
uninfected women. Thirty-seven (11.8%) white, 28 (3.7%) blacks/African Americans (AA), seven (3.3%) Hispanics/Latinas,
and one (6.6%) other race/ethnicity were heterozygous. The frequency of heterozygotes differed among sites for all
races combined (P = 0.001). More heterozygotes were found in AA women in Rhode Island (8.9%) than in the other
sites (3.1%) (P = 0.02), while
heterozygosity in white women was most common in Maryland (28.6%) (P = 0.025).
These regional differences could be accounted for by racial admixture in AAs, but not in whites. Regional variations
should be considered when studying host genetic factors and HIV-1 in US populations.
Genes and Immunity (2002) 3, 295–298. doi:10.1038/sj.gene.6363884
Polymorphism in the ß
chemokine receptor gene CCR5 affects HIV-1 entry, transmission, and outcome.1-3
Most people homozygous for a CCR5 gene variant (the 32 bp deletion (Δ32/Δ32))
are highly resistant to HIV-1 infection.3 HIV-infected individuals
heterozygous for CCR5 (+/Δ32) have about a 2-year delay in progression
to AIDS and slower CD4+ T cell decline compared with HIV infected individuals who do not carry the Δ32 polymorphism.4–6
We have examined the distribution of this gene in a cohort of United States
(US) women known as the HIV Epidemiology Research Study (HERS). This is a prospective,
multisite study conducted to define the epidemiologic, biologic, psychological, and social effects of
HIV-1 infection on the health of US women and to examine the progression of
HIV-1 disease.7 The HERS study focuses on women of various races
infected with or at high risk for HIV through heterosexual transmission and/or
through illicit drug injections. Seropositives and negatives were matched by
both distribution of race and by risk behavior in the HERS study design. A total
of 1310 HIV infected and uninfected women aged 16 to 55 years old were recruited between April 1993 and January 1995 at four study sites: New York
(NY), Michigan (MI), Maryland (MD), and Rhode Island (RI). Two of these sites
(MI, RI) recruited primarily from medical care/drug abuse therapy settings,
and two (NY, MD) from community sources. At all sites, HIV-1 uninfected women were recruited over the same time
period and from the same or comparable sources as the HIV-1 infected women.
The Institutional Review Boards at each institution approved the study.7
Baseline data on participant characteristics were previously published.7,8 Here, we report the
distribution of the CCR5-Δ32 gene in these women, by race/ethnicity, study
site, and HIV-1 status.
Racial admixture was defined as the presence of one or more parents or grandparents
reported as being of a different race than the self-identified racial or ethnic
group of the study participant. No information on the race or ethnicity of all
six parents and grandparents was treated as missing data for admixture (ie, admixture
could be underestimated). The proportions of missing admixture data were compared
among the sites by the X2 test. Chi-squared or two-tailed
Fisher’s exact test was used, when appropriate, to assess the
distribution of genotypes in the overall cohort, within racial groups and sites,
and in HIV-1 infected and uninfected women using SAS version 6.12 (SAS Institute,
Cary, NC, USA) and Epi-info (CDC, Atlanta, GA, USA). A P-value of less
than 0.05 was considered significant. The sample sizes of Hispanic, Asian, and
Native American groups were not large enough to provide statistical power for
stratification by site.
Genomic DNA was extracted from peripheral blood mononuclear cells (PBMC) by the
Puregene method (Gentra Systems Minneapolis, MN, USA). Detection of CCR5-Δ32 by
restriction fragment length polymorphism was performed using in house primers:
5'-CCTGGCTGTCGTCCATGCTG-3' and 5'-CTGATCTAG AGCC AT GTGCACAACTCT-3'. The PCR product was
digested with EcoR1, which resulted in two bands of 332 and 403 bp for the homozygous CCR5/CCR5
[+/+], two bands of 332 and 371 bp for the homozygous CCR5-Δ32/Δ32
[Δ32/Δ32], and three bands of 332, 371, and 403 bp for the heterozygous CCR5/Δ32 [+/Δ32].
We excluded from analysis six individuals whose DNA was depleted and three whose
DNA failed to amplify. Of the 1301 women genotyped for CCR5-Δ32,761 (58.5%)
identified themselves as black/African American (AA), 314 (24.1%) as white,
211 (16.2%) as Hispanic/Latina, 13 (1%) as Native American, and two (0.2%) as Asian. Regarding
HIV status, 422 women (32.4%) were HIV-1 uninfected and 879 (67.6%) were HIV-1
infected. Of the HIV-1 infected women, 865 (98.4%) were HIV seropositive at
enrollment and 14 (1.6%) seroconverted during the study. For this genetic analysis,
HIV-1 seroprevalent and seroconverting women were considered as one group. None
of the individuals in this study were homozygous for CCR5-Δ32, 73 (5.6%)
were heterozygous for CCR5 (+/Δ32), and 1228 (94.4%) were homozygous
for CCR5 (+/+). The distribution of the genotypes in the overall cohort was in
Hardy-Weinberg equilibrium (HWE) (Guo and Thompson HWE exact test;9 P = 0.62). Within each racial group and
in the HIV-1 infected and uninfected groups, the genotypes of the women were
also distributed according to the HWE.
The racial/ethnic group
distribution (in %) of CCR5-Δ32 heterozygosity was as follows: AA, 3.7%
(28/761); white, 11.8% (37/314); Hispanic/Latina, 3.3% (7/211); and other 6.6%
(1/15). The frequency of CCR5 heterozygotes in white women was similar to that
found in published data.1,3,10 Among the AA women this frequency
was similar to that reported in high risk AAs by Dean et al 3
(3.4%) but lower than that found in AA blood donors by Zimmerman10
(5.8%), although the difference was not statistically significant.
The CCR5-Δ32 heterozygous
genotype has been reported, although inconsistently, to influence HIV-1 transmission
in adults.1,3,4,10–12. We examined CCR5-Δ32 frequencies
in all racial groups in relation to HIV-1 status. There was no significant difference
in the frequency of CCR5 genotypes between HIV-1 infected and HIV-1 uninfected
women in the Hispanic/Latina, Asian, Native American (data not shown), AA or white groups (Table 1), which
is consistent with findings from other studies in adults3,4,10,11
showing no association with HIV-1 infection.
We then examined whether heterozygosity differed in frequency by site among
AAs and whites (groups with sufficient numbers to compare by site). The distribution
of the CCR5 genotypes among AAs at the four sites suggested differences among
the four sites (overall X2 test for heterogeneity = 6.801, P =
0.08). Investigation of the site data revealed the frequency of heterozygotes
to be significantly higher among AAs from Rhode Island (8.9%) compared with
the AA frequency in the other three sites combined (3.1%; X2
=5.15, P = 0.02) (Table 2). The CCR5 heterozygosity rate was significantly
higher (two-tailed Fisher’s test, P =0.03) than previously reported
for high risk AAs but not significantly different from the frequency in AA blood
donors.10 The frequency of heterozygotes in whites from RI (11.9%)
was no different than that observed in the other three sites combined (11.5%)
(X2= 0.01, P = 0.9), nor was the frequency of heterozygotes
different in all non-AAs from RI (10%) compared to non-AAs from the other three
sites combined (6.8%) (X2 = 1.82, P = 0.18). Thus, the high frequency
of CCR5 (+/Δ32) in AA from RI explains the high frequency of the genotype in all women at the RI study site.
A possible explanation for this higher frequency among AAs in RI could include
a higher rate of white racial admixture among AA women in RI compared with those
at other sites. For those who had available parental/and or grandparental lineage
data, we found that admixture of AAs with other races significantly differed among sites (overall
X2 for heterogeneity =45.14, P<0.0001). In RI,
this admixture was observed in 37 of 58 (63.8%) individuals compared to 56 of
186 (30.0%) women in MI, 53 of 233 (22.7%) in MD, and 20 of 109 (18.3%) in NY (RI
vs three other sites X2
= 39.9; P<0.0001). The percentages of missing data on admixture
in AA women were not significantly different among sites. The admixture rate
in RI appears to be high, although it may be limited by incorrect reporting
of parental and grandparental race.
We also found the distribution
of CCR5 heterozygotes among whites suggested differences exist among the sites
(X2 for heterogeneity among sites in whites, 8.50; P
= 0.037). Maryland had the highest frequency of heterozygotes (28.6%, 6/21),
which was significantly higher than that observed in RI, MI and NY whites combined
(10.6%, 31/293) (two-tailed Fisher’s test, P = 0.025).
We determined the presence
of racial admixture in whites. Four of 15 (26.7%) individuals in MD were admixed
with other races, compared to 4/33 (12.1%) in NY, 12/152 (7.9%) in RI, and 1/30
(3.3%) in MI. The 4 × 2 X2 for heterogeneity of racial
admixture in whites among sites was not possible because of small expected values,
but racial admixture in MD (26.7%) was higher than in the three other sites
combined (7.9%) (twotailed Fisher’s test, P = 0.037). However,
racial admixture of whites in MD was not associated with heterozygosity in the
direction that would explain higher rates of heterozygosity in this group. Admixture
of white with other races should result in a lower frequency of heterozygous
persons as we know that the presence of the CCR5-Δ32 polymorphism is lower
in AAs and other ethnic
groups. There was no significant difference in the percentages of missing data
on admixture among sites in whites.
We did not perform a quantitative genetic assessment of admixture in this study.
Instead we did a qualitative measurement by determining the frequency of study
subjects whose parents’ or grandparents’ racial/ethnic category
differed from the self-classified race/ethnicity of the participants. Estimates
of racial admixture can be obtained by other methods. For example, using Bernstein’s
formula13and a representative CCR5-Δ32 allele frequency of 0.092
in Caucasians1 and an intermediate frequency of 0.00714 in Africans1,14–17 we derived an estimate of white admixture in
the RI AA population of 43.5%. This was less than what we determined by self-assessment
(63.8%), but both methods suggest a significant degree of admixture in this
population. Williams et al 13 have shown in their
example that Bernstein’s formula and self-reported admixture approaches,
given their limitations, are valid qualitative measurement of racial admixture.
While determining if racial admixture influenced CCR5 gene distribution in US
populations was not the primary goal of the HERS study, these preliminary findings suggest that
racial admixture may be a possible explanation for the observed differences
among the sites.
Another factor that should
be considered is the impact of migration to or within the US. The well-known
geographic variation of CCR5-Δ32 frequencies in Europe and Eurasia, with
highest frequencies in Northern Europe,18,19 together with preferential
migration of certain European populations to certain US cities or states could
influence regional frequencies of CCR5, particularly among US whites. Unfortunately, the questionnaire administered to the participants of
this study did not collect information on the geographic origin of their ancestors.
The finding that CCR5-Δ32 frequencies vary regionally in the US is not
unexpected, as regional variation in the frequency of genes such as HLA has
been demonstrated in AAs20–22 and whites23 in the
US.
Overall, our findings suggest that regional differences in CCR5-Δ32 distribution
exist in AA and in white populations in the US. As the HIV epidemic in the US
is increasingly concentrated in non-white populations/racial groups,24
studies of the impact of host genetics on HIV-1 acquisition and disease progression
will need to consider the finding that CCR5 gene frequencies differ not only
between but also within racial groups.
Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1infection in Caucasian individuals bearing mutant alleles of the
CCR-5 chemokine receptor gene. Nature 1996; 382: 722725.
Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed
individuals to HIV-1 infection. Cell 1996; 86: 367377.
Dean M, Carrington M, Winkler C et al. Genetic restriction of
HIV-1 infection and progression to AIDS by a deletion of the
CKR5 structural gene. Science 1996; 273: 18561862.
Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
Nat Med 1996; 2: 12401243.
Michael NL, Chang G, Louie LG et al. The role of viral phenotype
and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat
Med 1997; 3: 338340.
Eugen-Olsen J, Iversen AK, Garred P et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival
and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305310.
Smith DK, Warren DL, Vlahov D et al. Design and baseline participant
characteristics of the human immunoldeficiency virus (HER) study: a prospective cohort study of human immunodeficiency
virus infection in US women. Am J Epidemiol 1997;146: 459469.
Solomon L, Styein M, Flynn C et al. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology
Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 253261.
Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles.
Biometrics 1992; 48:361372.
Zimmerman PA, Bucklerwhite A, Alkhatib G et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC
chemokine receptor 5 studies in populations with contrasting
clinical phenotypes, defined racial background, and quantified risk. Mol Med
1997; 3: 2336.
OBrien TR, Padian NS, Hodge T et al. CCR5 genotype and sexual transmission of HIV-1.
AIDS 1998; 12: 444445.
Burger H, Tarwater P, Kleeberger C et al. CCR5 genotype and susceptibility to transmission of HIV-1 to women. Abstract
No.WePeA3998. XIIIth International AIDS Conference, Durban,
South Africa, 914 July 2000.
Williams RC, Steinberg AG, Knowler WC, Pettitt DJ. Gm 3; 5, 13,14 and stated-admixture: independent estimates of admixture in
American Indians. Am J Hum Genet 1986; 39: 409413.
Kokkotou E, Philippon V, Gueye-Ndiaye A et al. Role of the CCR532 allele in resistance to HIV-1 infection in West Africa.
J Hum Virol 1998; 1: 469474.
Elharti E, Elaouad R, Simons M et al. Frequency of the CCR5
Δ32 allele in the Moroccan population. AIDS Res Hum Retrov
2000; 16: 8789.
Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion.
Nat Gen 1997: 16: 100103.
Lu C, Williams T, Makuwa M et al. Analysis of genetic polymorphism
of the HIV-coreceptor (CCR5) locus in a Gabonese population (abstract 044A297). Presented at Xth International Conference
on AIDS and STD in Africa, Abidjan, December 1997.
Stephens JC, Reich DE, Goldstein DB et al. Dating the origin of the CCR5-Delta 32 AIDS-resistance allele by the coalescence of
haplotypes. Am J Hum Genet 1998; 62: 15071515.
Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J Acquir Immune Defic Syndr Hum Retrovirol
1998; 19: 174177.
Acton RT, Harman L, Go RCP, Tseng ML, Bias W. Comparison of HLA phenotypes among African Americans from Alabama,
Maryland, and North Carolina. Transplant Proc 1993; 25: 24042407.
National Center for HIV, STD and TB prevention. Divisions of HIV/AIDS Prevention. HIV/AIDS among US Women: minority
and young women at continuing risk. Centers
for Disease Control and Prevention. Atlanta, GA.
http://www.cdc.gov/hiv/pubs/facts/women.htm
Correspondenc
e: JM McNicholl, Immunogenetics Laboratory, MSA25,NCID, 1600 Clifton Road, Atlanta, GA 30333, USA.
E-mail: jkm7_cdc.gov
MVD was supported by a CDC/ATPM Career Development Award Fellowship.
Received 26 October 2001; revised 1 March 2002; accepted 5 May 2002